Slide 1: 4Q FY2025 Financial Results Overview
4Q FY2025 FINANCIAL RESULTS OVERVIEW November 24, 2025
Slide 2: Safe Harbor
Thank You for Your Attention Safe Harbor This presentation contains forward- successfully adapt its cost structures to The company assumes no obligation to looking statements (including, without continuing changes in business update the information in these limitation, information, and future condit
Slide 3: Agilent 4Q25 Results
Agilent 4Q25 Results Revenue Beat, 200bps+ Op Margin expansion vs. Q3, 9% EPS growth $ • Revenue $1.86B, exceeds the high end of guide with Revenue Operating Margin EPS accelerating core growth(1) for 6 consecutive quarters • EPS $1.59(2), +9% YoY $1.86B 27.2% (2) $1.59 (2) +9.4% reported +7.2% core
Slide 4: Broad growth in Q4 led by LDG
Broad LDG +11% • Cont’d LC & LC/MS strength • CDMO (siRNA, GLP-1) drives Core Growth(1)(2) 22.7% Growth in Q4 growth and margins Operating Margin(2) +15% Reported led by LDG ACG +6% • +HSD growth in all regions except China All three segments meet Core Growth(1)(2) • Altura bio-inert LC column launc
Slide 5: Geography and product type growth
GEOGRAPHY PRODUCT TYPE The Americas and Americas Europe benefitting from 42% of Agilent Revenue(2) 11% (1) 0% (1) regionalization of 11% Europe (1) 28% of Agilent Revenue(2) supply chains driving GROWTH GROWTH GROWTH Asia-Pacific investment 30% of Agilent Revenue(2) (1) Core growth is reported growt
Slide 6: Q4 revenue mix
GEOGRAPHY PRODUCT TYPE % of total revenue Q4 revenue mix 65% Consumables Services Consumables, services, & Informatics informatics up 100 bps 35% year-over-year Instruments 06
Slide 7: Strong HSD+ growth in 5 largest end markets
Q4 Core Share Growth(1) of Agilent Results Revenue(2) +12% 37% Continued improvement with a pickup in activity at Pharma large US biopharma and excellent CDMO growth Q4 REVENUE Academia & Strong HSD+ NIH/US gov’t spending impact continues, while Europe Government and Asia slow down on more difficult
Slide 8: Initial FY26 Guidance
Net Initial $7.3B $7.4B FY26 Revenue ($) (1) Guidance Core Revenue Growth and margin Growth(2) +4% +6% +1% FX expansion driven by Ignite and improving Operating Margins +75 bps YoY & +9% growth at midpoint market conditions EPS $5.86 $6.00 $30M Net Interest + Other Inc/(Exp) $1.6-1.7B Operating $290
Slide 9: 1Q26 Guidance
1Q26 Guidance (1) Net Revenue ($B) $1.79B $1.82B Expecting continued Core Revenue +4% +6% strength in Pharma Growth(2) +2.5% FX and CAM driven by year- end capital spending EPS $1.35 $1.38 $8M Net Interest + Other Inc/(Exp) 285M Share Count Q1 Q1 (1) As of November 24, 2025, based on forecasted curr
Slide 10: Get in touch with us
Get in touch with us Trusted Answers investor_relations@agilent.com www.investor.agilent.com